Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some vaccine-related statements align with the label (e.g., avoid live vaccines; clinical effectiveness of influenza vaccine not assessed). However, several claims are unsupported or too specific (e.g., vaccine effectiveness timing, inactivated vs live nasal designation, reduced immune response specifics, and general recommendations about timing/monitoring/antivirals) and the response omits label-required pre-treatment evaluations (e.g., TB assessment) relevant to safety around immunomodulation.
Category Scores
Accurate Statements
Live vaccines are avoided with COSENTYX / Avoid use of live vaccines in patients treated with COSENTYX.
Section 5.7 – “COSENTYX may alter a patient's immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX.”
COSENTYX may alter a patient's immune response to live vaccines.
Section 5.7 – “COSENTYX may alter a patient's immune response to live vaccines.”
The label indicates clinical effectiveness of influenza vaccine has not been assessed in patients undergoing treatment with COSENTYX.
Section 12.2 – “The clinical effectiveness of meningococcal and influenza vaccines has not been assessed in patients undergoing treatment with COSENTYX.”
COSENTYX may increase the risk of infections / infections occur at higher rates than placebo in trials.
Section 5.1 – “COSENTYX may increase the risk of infections.” and Section 6.1 – “Infections were reported in 28.7% of subjects treated with COSENTYX compared with 18.9% of subjects treated with placebo.”
If an anaphylactic or other serious allergic reaction occurs, discontinue COSENTYX immediately.
Section 5.2 – “If an anaphylactic or other serious allergic reaction occurs, immediately discontinue administration of COSENTYX…”
Unsupported Statements
By blocking IL-17A, Cosentyx can reduce the immune response to vaccines.
Label excerpt provided supports immune response alteration to live vaccines (Section 5.7) but does not state a general mechanism-to-vaccine claim specifically 'reduce the immune response to vaccines' broadly.
Cosentyx may lower how strongly you respond to a flu shot.
Label excerpt does not state reduced response to influenza vaccines in particular; it only states live vaccine immune response alteration (Section 5.7) and that influenza vaccine effectiveness has not been assessed (Section 12.2).
A flu vaccine is still generally considered useful because it can provide protection even if the immune response is not as strong.
No such statement appears in the provided label excerpts (Sections 5.7 and 12.2 indicate uncertainty for effectiveness and live vaccine avoidance rather than general usefulness).
In routine use, people taking Cosentyx are typically advised to get inactivated vaccines such as the standard flu shot (not the live nasal spray).
Label excerpt provided does not recommend inactivated influenza vaccination specifically; it states to complete vaccinations prior to initiating and to avoid live vaccines during treatment (Sections 2.1 and 5.7).
The flu shot is inactivated. The nasal flu mist is a live-attenuated vaccine.
Vaccine-specific formulation (inactivated vs live-attenuated) is not addressed in the provided COSENTYX prescribing information excerpts.
The nasal flu mist is generally not recommended for people on immune-modifying treatments.
The label only advises avoiding live vaccines in patients treated with COSENTYX (Section 5.7); it does not provide guidance about 'nasal flu mist' or immunomodifying treatments generally.
Guidelines for vaccine timing vary by condition and local practice.
The label excerpt does not provide such general timing guidance.
For biologics, clinicians often try to vaccinate when immune suppression is at its lowest (for example, not right after the latest dose).
The provided label excerpts do not specify vaccine timing relative to dosing intervals.
A prescriber can help choose timing based on a dosing schedule and infection risk.
The label excerpt provides vaccination completion prior to initiation (Section 2.1) but does not endorse dosing-schedule-based timing for vaccination.
If you are immunosuppressed, practical steps include getting vaccinated every season.
No statement in the provided label excerpts recommends seasonal vaccination frequency.
If recommended, early antiviral treatment can improve outcomes when flu-like symptoms develop.
The provided COSENTYX prescribing information excerpts do not discuss antivirals for influenza-like symptoms.
People with additional risk factors such as older age, chronic lung disease, diabetes, or other immunosuppressive medications are more likely to experience weaker vaccine responses or more severe illness.
The provided label excerpts do not state these risk-factor relationships for vaccine response or illness severity.
Guidelines/avoidance statements about live vaccines 'with biologic immune-modulating therapies' are more general than the label excerpt.
Label excerpt specifically states to avoid live vaccines in patients treated with COSENTYX (Section 5.7), not all biologic immune-modulating therapies.
Contradictions
Important Omissions
COSENTYX requires pre-treatment evaluation for active or latent tuberculosis (TB) and latent TB treatment prior to initiation; initiation is not recommended in active TB infection.
Importance:
Moderate
A vaccination-related label instruction to complete all age-appropriate vaccinations prior to initiating COSENTYX (not just general vaccine advice).
Importance:
Moderate
Specific label wording that COSENTYX may alter immune response to live vaccines and that live vaccines should be avoided; the response did not clearly anchor to that 'live vaccines' limitation in all vaccine statements (it broadened to flu/inactivated claims).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Some label-consistent caution about live vaccines is included, but several statements expand beyond the label (e.g., reduced response to flu shots, inactivated vs live nasal mist specifics, and general usefulness/timing/antiviral guidance). These could mislead about vaccination expectations and management, and the response omits key label safety steps (TB evaluation and vaccination completion prior to initiation).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several vaccine and flu-shot specifics are not supported by the provided COSENTYX label excerpts (formulation, expected immune-response reduction, season/timing, antivirals, and risk-factor generalizations).
Suggested Improvement
Limit statements to label-supported points: (1) complete age-appropriate vaccinations per guidelines prior to initiation; (2) avoid live vaccines during treatment because COSENTYX may alter immune response to live vaccines; (3) do not assert flu-shots or live nasal mist formulation/expected response changes beyond what the label provides; (4) include label-required pre-treatment evaluation for TB and monitoring guidance relevant to infection risk.